Why the study?
Does a personalized pharmacogenetic approach reduce the incidence of statin-associated muscle symptoms and optimize adherence in patients with or at risk of ASCVD?
Does a personalized pharmacogenetic approach reduce the incidence of statin-associated muscle symptoms and optimize adherence in patients with or at risk of ASCVD?
Understanding the pharmacogenetic basis of statin-associated muscle symptoms may enable personalized approaches to improve statin adherence and reduce cardiovascular risk.
No takes yet. Share an insight, caveat, or question.
SAMS variability supports individualized adherence counseling; leaves open genetic contributions pending prospective validation.
Brunham et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: